Vaccination against nicotine: An emerging therapy for tobacco dependence

Expert Opinion on Investigational Drugs

Volumn 16, Issue 11, 2007, Pages 1775-1783

  Maurer, Patrik ^a   Bachmann, Martin ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

Addiction; Nicotine; Relapse prevention; Smoking cessation; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; AMFEBUTAMONE; ANTIBODY; CANNABINOID RECEPTOR ANTAGONIST; CHOLERA TOXIN; DIANICLINE; DOPAMINE RECEPTOR BLOCKING AGENT; GW 468816; NICOTINE; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC AGENT; NICQB; PLACEBO; RIMONABANT; SURINABANT; UNCLASSIFIED DRUG; VARENICLINE; CARRIER PROTEIN; NICOTINE QBETA VACCINE; VACCINE;

ABSTINENCE; CLINICAL TRIAL; DREAM; DRUG MECHANISM; FLU LIKE SYNDROME; HUMAN; INJECTION SITE REACTION; INSOMNIA; NAUSEA; NONHUMAN; REINFORCEMENT; REVIEW; REWARD; SIDE EFFECT; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; VACCINATION; VIRUS LIKE AGENT; WITHDRAWAL SYNDROME; ANIMAL; IMMUNOLOGY; METHODOLOGY;

ANIMALS; CARRIER PROTEINS; HUMANS; NICOTINE; SMOKING CESSATION; TOBACCO USE DISORDER; VACCINATION; VACCINES;

EID: 36049039339     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.11.1775     Document Type: Review

References (56)

1. WHO: WHO Tobacco Free Initiative: Building Blocks for Tobacco Control: A Handbook (Ed.), WHO, Geneva, Switzerland (2004):3-13.
2. SURGEON G: The Health Consequences of Smoking: A Report of the Surgeon General. (Ed.), Department of Health and Human Services, Centers for Disease, Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Washington, DC, USA (2004).
3. GAJALAKSHMI V, PETO R, KANAKA TS, JHA P: Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet (2003) 362(9383):507-515.
4. RIGOTTI NA: Clinical practice. Treatment of tobacco use and dependence. N. Engl. J. Med. (2002) 346(7):506-512.
5. LE FOLL B, GOLDBERG SR: Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl.) (2005):1-15.
6. HARVEY DM, YASAR S, HEISHMAN SJ et al.: Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl.) (2004) 175(2):134-142.
7. HUKKANEN J, JACOB P III, BENOWITZ NL: Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. (2005) 57(1):79-115.
8. NESTLER EJ: Is there a common molecular pathway for addiction? Nat. Neurosci. (2005) 8(11):1445-1449.
9. FAGERSTROM K, BALFOUR DJ: Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin. Investig. Drugs (2006) 15(2):107-116.
10. LAVIOLETTE SR, VAN DER KOOY D: The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. (2004) 5(1):55-65.
11. PIASECKI TM: Relapse to smoking. Clin. Psychol. Rev. (2006) 26(2):196-215.
12. KALMAN D, MORISSETTE SB, GEORGE TP: Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am. J. Addict., An. Acad. Psychiatr. Alcohol Addict. (2005) 14(2):106-123.
13. HUGHES JR, GUST SW, SKOOG K, KEENAN RM, FENWICK JW: Symptoms of tobacco withdrawal. A replication and extension. Arch. Gen. Psychiatry (1991) 48(1)52-59.
14. JORENBY DF, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. (1999) 340(9):685-691.
15. SILAGY C, LANCASTER T, STEAD L, MANT D, FOWLER G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. (2004) 3:CD000146.
16. HUGHES J, STEAD L, LANCASTER T: Antidepressants for smoking cessation. Cochrane Database Syst. Rev. (2007) 1:CD000031.
17. COE JW, BROOKS PR, VETELINO MG et al.: Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. (2005) 48(10):3474-3477.
18. JORENBY DE, HAYS JT, RIGOTTI NA et al.: Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 296(1)56-63.
19. GONZALES D, RENNARD SI, NIDES M et al.: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):47-55.
20. TONSTAD S, TONNESEN P, HAJEK P et al.: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 296(1):64-71.
21. COHEN C, BERGIS OE, GALLI F et al.: SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. (2003) 306(1):407-420.
22. KOSOWSKI AR, CEBERS G, CEBERE A, SWANHAGEN AC, LILJEQUIST S: Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551. Psychopharmacology (Berl.) (2004) 175(1):114-123.
23. COHEN C, PERRAULT G, GRIEBEL G, SOUBRIE P: Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology (2005) 30(1):145-155.
24. LE FOLL B, GOLDBERG SR, SOKOLOFF P: Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin. Investig. Drugs (2007) 16(1):45-57.
25. BONESE KF, WAINER BH, FITCH FW, ROTHBERG RM, SCHUSTER CR: Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature (1974) 252(5485):708-710.
26. KENFORD SI., FIORE MC, JORENBY DE et al.: Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA (1994) 271(8):589-594.
27. SHIFFMAN S, FERGUSON SG, GWALTNEY CJ: Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl.) 184(3-4):608-618.
28. ROSE JE: Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl.) (2006) 184(3-4):274-285.
29. WATKINS SS, KOOB GF, MARKOU A: Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. (2000) 2(1):19-37.
30. HIEDA Y, KEYLER DE, VANDEVOORT JT et al.: Active immunization alters the plasma nicotine concentration in rats. J. Pharmacol. Exp. Ther (1997) 283(3):1076-1081.
31. PENTEL PR, MALIND H, ENNIFAR S et al.: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. (2000) 65(1):191-198.
32. ISOMURA, S, WIRSCHING P, JANDA KD: An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J. Org. Chem. (2001) 66(12):4115-4121.
33. LINDBLOM N, DE VILLIERS SH. KALAYANOV G et al.: Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Repiration (2002) 69(3):254-260.
34. CERNY EH, LEVY R, MAUEL J et al.: Preclinical deve1opment of a vaccine 'against smoking'. Onkologie (2002) 25(5):406-411.
35. SANDERSON SD, CHERUKU SR, PADMANILAYAM MP et al.: Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int. Immunopharmacol. (2003) 3(1):137-146.
36. MEIJLER MM, MATSUSHITA M, ALFOBELL LJ III, WIRSCHING P, JANDA KD: A new strategy for improved nicotine vaccines using conformationally constrained haptens. J. Am. Chem. Soc. (2003) 125(24):7164-7165.
37. MAURER P, JENNINGS GT, WILLERS J et al.: A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. (2005) 35(7):2031-2040.
38. DE VILLIERS SH, LINDBLOM N, KALAYANOV G et al.: Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn Schmiedeberg Arch. Pharmacol. (2004) 370(4):299-304.
39. DE VILLIERS SH, LINDBLOM N, KALAYANOV G et al.: Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration (2002) 69(3):247-253.
40. LESAGE MG, KEYLER DE, HIEDA Y et al.: Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl.) (2006) 184(3-4):409-416.
41. MALIN DH, LAKE JR, LIN A et al.: Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. (2001) 68(1):87-92.
42. HUGHES JR, KEELY JP, NIAURA RS et al.: Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. (2003) 5(1):13-25.
43. WEST R, HAJEK P, STEAD L, STAPLETON J: Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction(2005) 100(3):299-303.
44. JEGERLEHNER A, TISSOT A, LECHNER F et al.: A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 20(25-26):3104-3112.
45. BACHMANN MF, ROHRER UH, KUNDIG, TM et al.: The influence of antigen organization on B cell responsiveness. Science (1993) 262(5138):1448-1451.
46. KUNDIG TM, SENTI G, SCHNETZLER G et al.: Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. (2006) 117(6):1470-1476.
47. AMBUHL PM, TISSOT AC, FULURIJA A et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and Phase I safety and immunogenicity. J. Hypertens. (2007) 25(1):63-72.
48. CORNUZ J, KLINGLER K, MUELLER P, JUNGI, F, CERNY , T: A therapeutic vaccine for nicotine dependence: results of a Phase I and a randomized Phase II study. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S):1008.
49. HIEDA Y, KEYLER DE, VANDEVOORT JT et al.: Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl.) (1999) 143(2):150-157.
50. SATOSKAR SD, KEYLER DE, LESAGE MG et al.: Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int. Immunopharmacol. (2003) 3(7):957-970.
51. KEYLER DE, SHOEMAN D, LESAGE MG, CALVIN AD, PENTEL PR: Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J. Pharmacol. Exp. Ther. (2003) 305(2):587-592.
52. HATSUKAMI DK, RENNARD S, JORENBY D et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol Ther. (2005) 78(5):456-467.
53. LINDBLOM N, DE VILLIERS SH, SEMENOVA S et al.: Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch. Pharmacol. (2005):1-13.
54. MIRE-SLUIS AR, BARRETT YC, DEVANARAYAN V et al.: Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods (2004) 289(1-2):1-16.
55. HASMAN A, HOLM S: Nicotine conjugate vaccine: is there a right to a smoking future? J. Med. Ethics (2004) 30(4):344-345.
56. HALL WD: Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med. (2005) 2(9):E266.